Real-World Studies
Anlotinib Monotherapy in Heavily Pretreated or Temozolomide-Ineligible Recurrent Malignant Glioma
Sun et alTranslational Cancer Research
In patients with recurrent malignant glioma who have exhausted standard therapeutic options or are ineligible for further temozolomide or re-irradiation, effective systemic treatments remain limited. A retrospective real-world study evaluated the feasibility, safety, and preliminary antitumor activity of anlotinib monotherapy, a multi-target angiogenesis inhibitor, in this heavily pretreated population.
The cohort included 18 patients who received oral anlotinib at an initial dosage of 12 mg once daily on days 1–14 of 21-day cycles until radiographic progression, unacceptable toxicity, withdrawal, or death. Over a median follow-up of 9.2 months (range, 3.1–18.4 months) estimated using the reverse Kaplan-Meier method, the primary endpoint of 6-month progression-free survival (PFS) was 66.7% (95% CI: 42.0–91.4%), and median PFS was not reached at the data cutoff. Objective response was documented in 38.9% of patients (7/18; 95% CI: 17.3–64.3%), while the disease control rate reached 88.9% (16/18; 95% CI: 65.3–98.6%).
Patients received a median of 9 treatment cycles (range, 2–24 cycles), corresponding to a median treatment duration of 6.3 months (range, 1.4–16.8 months). Overall, anlotinib displayed manageable tolerability; most treatment-emergent adverse events were grade 1 or 2. Dose modifications occurred in a subset of patients, with 6 individuals (33.3%) requiring temporary treatment interruptions and 3 (16.7%) requiring dose reductions to 10 mg daily. One patient (5.6%) experienced grade 3 thrombocytopenia, and no treatment-related fatalities occurred. Overall survival data were immature at the time of analysis, and the authors noted that prospective validation is required to confirm these preliminary findings.
Key Takeaways
- Anlotinib monotherapy achieved an estimated 6-month progression-free survival rate of 66.7% (95% CI: 42.0–91.4%), an objective response rate of 38.9% (95% CI: 17.3–64.3%), and a disease control rate of 88.9% (95% CI: 65.3–98.6%) in heavily pretreated or temozolomide-ineligible recurrent malignant glioma.
- Adverse events were predominantly grade 1 to 2, with 33.3% of patients requiring temporary interruptions, 16.7% needing dose reductions from 12 to 10 mg daily, and one patient (5.6%) experiencing grade 3 thrombocytopenia, with no treatment-related deaths reported.
Read the original sourceTranslational Cancer Research
